Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy

Leukemia volume 18, pages 2044–2046 (2004)Cite this article

TO THE EDITOR

In multiple myeloma (MM) patients, treatment with thalidomide has proven its efficacy as monotherapy, but also combined with dexamethasone and chemotherapy. However, in combination with these drugs thalidomide may increase the incidence of deep venous thrombosis and pulmonary embolism up to 30%.1

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614–1615.

    Article  CAS  PubMed  Google Scholar 

  2. Cavenagh JD, Oakervee H . Thalidomide in multiple myeloma: current status and future prospects. Br J Haematol 2003; 120: 18–26.

    Article  CAS  PubMed  Google Scholar 

  3. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55–65.

    CAS  PubMed  Google Scholar 

  4. Osman K, Comenzo R, Rajkumar SV . Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 2001; 344: 1951–1952.

    Article  CAS  PubMed  Google Scholar 

  5. Zervas K, Dimopoulos MA, Hatzicharissi E, Anagnostopoulos A, Papaioannou M, Mitsouli Ch, et al., Greek Myeloma Study Group. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol 2004; 15: 134–138.

    Article  CAS  PubMed  Google Scholar 

  6. Minnema MC, Fijnheer R, De Groot PG, Lokhorst HM . Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 2003; 1: 445–449.

    Article  CAS  PubMed  Google Scholar 

  7. Cavo M, Zamagni E, Cellini C, Tosi P, Cangini D, Cini M et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 2002; 100: 2272–2273.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. I Breitkreutz and J J A Auwerda: Both authors contributed equally to the study

Authors and Affiliations

  1. University Medical Center Utrecht, The Netherlands

    M C Minnema, A M W van Marion & H M Lokhorst

  2. Heidelberg Medical University, Germany

    I Breitkreutz, F W Cremer & H Goldschmidt

  3. Erasmus Medical Center Rotterdam, The Netherlands

    J J A Auwerda & P Sonneveld

  4. Hovon Data Center, Rotterdam, The Netherlands

    B van der Holt & P H M Westveer

Authors
  1. M C Minnema
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I Breitkreutz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J J A Auwerda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B van der Holt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F W Cremer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A M W van Marion
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P H M Westveer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P Sonneveld
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H Goldschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H M Lokhorst
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H M Lokhorst.

Additional information

Presented partly as abstract at the 9th International Workshop 2003, Salamanca, Spain

Rights and permissions

Reprints and permissions

About this article

Cite this article

Minnema, M., Breitkreutz, I., Auwerda, J. et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 18, 2044–2046 (2004). https://doi.org/10.1038/sj.leu.2403533

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403533

This article is cited by

Search

Advanced search

Quick links